TRAF4 and central nervous system cancer: Our results underscore the practical values of these molecules as novel biomarkers for glioma grading and prognostic assessment, and imply that miR-29a/b/c and TRAF4 can be used as therapeutic candidates and as a target for malignant glioma, respectively.